New tafamidis tablet could be easier to swallow

NCT ID NCT07587697

Ongoing Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial compares a new orally disintegrating tablet (ODT) of tafamidis to the standard capsule in 15 healthy adults. Participants receive single doses of each form under fasting conditions to measure drug levels in the blood. The goal is to see if the ODT works the same as the capsule, potentially offering a more convenient option for patients who have trouble swallowing pills.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tafamidis
What this could lead to: If successful, this could show that the new orally disintegrating tablet works as well as the current capsule, offering a more convenient option for patients.
What could go wrong: This is a very early, small study in healthy people, not patients. It only checks blood levels, not whether the drug actually treats disease. The new form might not prove equivalent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULTS

Contacts and locations

Locations

P-One Clinic

Hachioji-shi, Tokyo, 1920071, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.